Century Therapeutics, Inc. · NASDAQ:IPSC
Century Therapeutics — Investor Presentation (August 2023)
25 slides from Century Therapeutics's investor presentation, Aug 9, 2023
Slide 1: Corporate Overview
)) CENTURY 4p THERAPEUTICS Corporate Overview Aug 2023
Slide 2: Forward-looking statements
2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or
Slide 3: Investment Thesis
3 Investment Thesis Next generation platforms for iNK and gamma delta iT candidates Foundational investments in iPSC technology, genetic editing, and manufacturing Experienced team in R&D, immuno-oncology, manufacturing and commercialization Exemplified by FDA clearance of Century’s first IND for CN
Slide 4: Century Therapeutics
CENTURY THERAPEUTICS
Slide 5: Building a next generation allogeneic cell therapy platform
5 Building a next generation allogeneic cell therapy platform Gene Editing • Proprietary gene editing platform • CRISPR MAD7-derived gene editing for precise transgene integration Protein Engineering • Developing proprietary next-generation CARs • Universal tumor targeting platform iPSC Differentiat
Slide 6: Foundational investments in iPSC know-how and manufacturing
6 Foundational investments in iPSC know-how and manufacturing Established in-house manufacturing accelerates learnings and enables faster product iteration • 53,000 ft2 facility • Designed to produce multiple immune cell types • Two sites provides optionality and maximizes flexibility iPSC license a
Slide 7: Multiple gene edits (KO/KI) iPSC bank
7 Multiple gene edits (KO/KI) iPSC bank Precision CRISPR MAD7 mediated sequential gene editing of iPSC cells generates uniform product candidates Engineered iPSC Master Cell Bank (MCB) Advantages of Century’s Platform Precise CRISPR mediated homology directed repair reduces off-target integration St
Slide 8: Potential to drive durable responses with engineering to resist immune rejection
8 Potential to drive durable responses with engineering to resist immune rejection Allo-EvasionTM edits + repeat dosing = potential greater durability Next-wave of allogeneic cell therapies must solve for challenge of rejection With Allo-EvasionTM engineering Without Allo-EvasionTM engineering
Slide 9: Allo-Evasion 1.0 designed to overcome major pathways of host vs graft rejection
9 Allo-EvasionTM 1.0 designed to overcome 3 major pathways of host vs graft rejection 1. Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells 2. Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells 3. Knock-in of
Slide 10: Allo-Evasion 3.0 Provides Additional Protection Against NK Cell Killing
10 Allo-EvasionTM 3.0 Provides Additional Protection Against NK Cell Killing 1. Deletion of β2M, a protein required to express HLA-1 on the cell surface prevents recognition by CD8 T cells 2. Knock out of CIITA eliminates HLA-II expression to escape elimination by CD4 T cells 3. Knock-in of HLA-E pr
Slide 11: Expression of HLA-E + HLA-G further protects from NK cell killing
11 Expression of HLA-E + HLA-G further protects from NK cell killing HLA-E HLA-G NKG2A KIRs, LIRs Activating ligand Activating receptor Proof-of-Concept Study with HLA-I Null K562 Cells Engineered with HLA-E and HLA-G 0.125 0.25 0.5 1 2 4 8 16 32 0 20 40 60 80 100 Donor RC01 Ratio (E:T) % Killing Pa
Slide 12: Pipeline
Pipeline
Slide 13: Product candidate pipeline across cell platforms and targets
13 Product iPSC Platform Targets Indications Discovery Preclinical Clinical Collaborator P1 P2 P3 CNTY-101 iNK CD19 B-Cell Malignancies CNTY-102 iT CD19 + CD22 B-Cell Malignancies CNTY-107 iT Nectin-4 Solid Tumors Programs in Collaboration CNTY-104 iNK/iT Multi-specific Acute Myeloid Leukemia CNTY-1
Slide 14: Promise of allogeneic cell therapies in lymphoma
14 Promise of allogeneic cell therapies in lymphoma Large unmet need remains despite progress with autologous cell therapies • ~25% of eligible patients receive CAR-T therapy1 • ~35% of patients achieve long-term remission even in earlier lines of therapy1 Off-the-shelf modalities approaching bar se
Slide 15: CNTY-101: Differentiated next-gen CD19 targeted product
15 Delivering on our vision to change the cell therapy treatment paradigm • Goal to improve durability, tolerability and ease of outpatient administration • Potential to eliminate need for lymphodepletion with subsequent cycles of therapy • First CD19-targeted agent to test durability benefit of rep
Slide 16: CNTY-101 shows strong pre-clinical anti-tumor activity
16 CNTY-101 shows strong pre-clinical anti-tumor activity In Vitro Serial killing assay Robust activity against lymphoma xenograft Borges, et al, ASH 2021
Slide 17: ELiPSE-1: Ongoing first-in-Human Study
17 ELiPSE-1: Ongoing first-in-Human Study CNTY-101 in patients with patients with relapsed/refractory CD19+ B-cell lymphomas Study to assess: Impact of Allo-EvasionTM on iNK cell persistence and PK after multiple dosing (Schedule B) Multiple dose regimen with up to 6 doses with single lymphodepletio
Slide 18: ELiPSE-1 translational endpoints
t 8 , 2 0 2 3 1 8 Lymphodepletion, Century product infusion CNTY-101 CRP IL-15 % VAF Blood Serum/ Plasma Tumor Biopsy Mechanism of Action/ Resistance Safety & Other Efficacy Correlates Pharmacokinetics: Expansion & Persistence Phenotype & function Homeostatic cytokines, IL-2 Minimum residual disease
Slide 19: CNTY-102: Leveraging the γδ iT platform
19 CNTY-102: Leveraging the γδ iT platform designed to deliver best-in-class potential HLA-II KO Illustrative construct γδTCR/CD3 IL-15/IL15RA HLA-E HLA-G HLA-I KO CD19/CD22 loop CAR Designed to address factors that limit durability of cell therapy in B-cell malignancies • γδ iT cells demonstrate hi
Slide 20: Vision for winning in solid tumors with γδ iT platform
20 Vision for winning in solid tumors with γδ iT platform Trafficking and infiltration γδ iT cells - tissue homing TME / Immunosuppressive environment Requirement for chemotherapy conditioning Tumor heterogeneity • Novel conditioning regimens • Genetic engineering Challenges Century’s Solution Futur
Slide 21: iPSC-derived γδ T cells effective at tumor control as monotherapy and in combination
21 iPSC-derived γδ T cells effective at tumor control as monotherapy and in combination with antibody Millar, et al, SITC 2022 γδ-EGFR-CAR-T cells demonstrate significant CAR killing of ovarian spheroids γδCAR-T demonstrate additive efficacy in combination with trastuzumab Treatment % TGI Significan
Slide 22: CNTY-107: First in class Nectin-4 targeted γδ iT cell therapy
22 CNTY-107: First in class Nectin-4 targeted γδ iT cell therapy Leveraging the power of the γδ iT cell platform for solid tumors Nectin-4 has been validated by ADC approaches • Opportunity to address multiple Nectin-4 positive solid tumors • Potential indications include bladder, breast, pancreatic
Slide 23: Investment Thesis
23 Investment Thesis Next generation platforms for iNK and gamma delta iT candidates Foundational investments in iPSC technology, genetic editing, and manufacturing Experienced team in R&D, immuno-oncology, manufacturing and commercialization Exemplified by FDA clearance of Century’s first IND for C
Slide 24: Emerging leader in cell therapies for cancer
Emerging leader in cell therapies for cancer Comprehensive iPSC cell platform For immune effector cells Technical Expertise Genetic and protein engineering, process development and immuno-oncology Foundation in Science Continuing investment in innovation drives R&D State-of-the-art GMP manufacturing
Slide 25: Thank you.
jf THERAPEUTICS (C )) CENTURY Thank you.
Century Therapeutics — Investor Presentation (August 2023) on 6ix